Russia may return to issue of forced transfer of licenses of innovative foreign drugs

Members of the Russian Parliament have not ruled out the possibility of the beginning forced transfer of licenses for the production of innovative drugs in Russia in case of exodus of their producers from the local market, The Pharma Letter’s local correspondent reports.

This has been recently confirmed by Federation Council Speaker Valentina Matviyenko, according to whom Russian companies may be allowed to apply for a compulsory license for the production of drugs if clinical trials are not conducted, while foreign pharmaceutical companies do not apply for drug registration.

According to Ms Matvienko, the withdrawal of foreign pharmaceutical companies from the Russian market cannot serve as a force majeure circumstance for them.